Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1989-03-15
1991-11-26
Lee, Lester L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
A61K 3702
Patent
active
050682237
ABSTRACT:
Esters or amides of a peptide, preferebly a dipeptide, consisting essentially of natural or synthetic L-amino acids with hydrophobic side chains were found to have specific cellular toxicities. Preferable amino acids of the peptide are leucine, phenylalanine valine, isoleucine, alanine, proline, glycine or aspartic acid beta methyl ester. Preferable dipeptides are L leucyl L-leucine, L-leucyl L-phenylalanine, L-valyl L-phenylalanine, L-Leucyl L-isoleucine, L-henylalanyl L-phenylalanine, L-valyl L-leucine, L-leucyl L-alanine, L-valyl L-valine, L-phenylalanyl L leucine, L prolyl L-leucine, L-leucyl L-valine, L-phenylalanyl L-valine, L glycyl L-leucine, L-leucyl L-glycine, glycyl L-phenylalanine and L-aspartyl beta methyl ester L-phenylalanine. Most preferable dipeptides are L-leucyl L-leucine, L-leucyl L-phenylalanine, L-valyl L-phenylalanine, L-phenylalanyl L-leucine, L-leucyl L-isoleucine L-phenylalanyl L-phenylalanine and L-valyl L-leucine.
The ester or amide of the dipeptide is most preferably alkyl, aralkyl or aryl a preferred alkylester is a methyl ester and may also be an ethyl ester or alkyl of up to about four carbon atoms such as propyl, isopropyl, butyl or isobutyl. Yet larger alkyl substituents may also be functional judging from the beta naphthyl substituent which is functional in certain embodiments.
These alkyl, aryl or arylkyl esters and amides of dipeptides consist essentially of amino acids with hydrophobic side chains may be used to deplete cytotoxic T-lymphocytes or natural killer cells from organisms, cell populations or tissues.
REFERENCES:
patent: 4555502 (1985-11-01), Patchett et al.
patent: 4585757 (1986-04-01), Pang et al.
patent: 4616012 (1986-10-01), Neustadt et al.
patent: 4752602 (1988-06-01), Lipsky et al.
Goldman et al., Dipeptide Hydrolysis within Intact Lysosomes in Vitro, North Holland Publishing Company-Amsterdam, vol. 33, No. 2, pp. 208-212.
Reeves et al., Accumulation of Amino Acids by Lysosomes Incubated with Amino Acid Methyl Esters*, The Journal of Biological Chemistry, vol. 254, No. 18, pp. 8914-8921.
Thiele et al., Phenotype of the Accessory Cell Necessary for Mitogen-Stimulated T and B Cell Response in Human Peripheral Blood: Delineation by its Sensitivity to the Lysosomotropic Agent, L-Leucine Methyl Ester, The Journal of Immunology, vol. 13, No. 5., Nov. 1983, pp. 2282-2290.
Verhoef et al., Inhibition of Human Natural Killer Activity by Lysosomotropic Agents, The Journal of Immunology, vol. 131, No. 1, Jul. 1983, pp. 125-131.
Shau et al., Depletion of NK Cells with the Lysosomotropic Agent L-Leucine Methy; Ester and the In Vitro Generation of NK Activity from NK Precursor Cells, The Journal of Immunology vol. 134, No. 2, Feb. 1985, pp. 1136-1141.
Trinchieri et al., Anti-Viral Activity Induced by Culturing Lumphocytes with Tumor-Derived or Virus-Transformed Cells, The Rockefeller University Press, 0022-1007/78/0501-1314, pp. 1314-1333.
Charley et al., Prevention of Lethal Murine Graft Versus Host Disease by Treatment of Donor Cells with L-Leucyl-1-Leucine Methyl Ester, The American Society for Clinical Investigation, Inc., vol. 78, Nov. 1986, pp. 1415-1420.
Thiele et al., Lethal Graft-VS-Host Disease Across Major Histocompatibility Barriers: Requirement for Leucyl-Leucine Methyl Ester Sensitive Cytotoxic Cells, The Journal of Immunology, vol. 138, No. 1, Jan. 1, 1987. pp. 51-57.
Gidlund et al., Enhanced NK Cell Activity in Mice Injected with Interferon and Interferon Inducers, Naurte, vol. 273, Jun. 29, 1978, pp. 759-761.
Lopez et al., Association Between Pre-Transplant Natural Kill and Graft-Versus-Host Disease After Stem-Cell Transplantation, The Lancet, Nov. 24, 1978, pp. 1103-1106.
Seeley et al., Studies on Cytotoxicity Generated in Human Mixed Lymphocyte Cultures, The Journal of Immunology, vol. 123, No. 3, Sep. 1979, pp. 1303-1311.
Roder et al., Traget-Effector Interaction in The Natural Killer Cell System, The Journal of Immunology, vol. 123, No. 6, Dec. 1979, pp. 2785-2790.
Kendall et al., The Dual Effect of Prostaglandin (PGE.sub.2) and Ethanol on the Natural Killer Cytolytic Process: Effector Activation and NK-Cell-Traget Cell Conjugate Lytic Inhibition, The Journal of Immunology, vol. 125, No. 6, Dec. 1980, pp. 2770-2777.
Lopez et al., Natural Killer Cells in Bone Marrow Transplantation, The Lancet, Nov. 8, 1980, p. 1025.
Breard et al., A Monoclonal Antibody Reactive with Human Peripheral Blood Monocytes, The Journal of Immunology, vol. 124, No. 4, Apr. 1980, pp. 1943-1948.
Zarling, et al., Phenotypes of Human Natural Killer Cell Populations Detected with Monoclonal Antibodies, The Journal of Immunology, vol. 127, No. 6, Dec. 1981, pp. 2575-2580.
Ortaldo et al., Determination of Surface Antigens on Highly Purified Human NK Cells by Flow Cytometry with Monoclonal Antibodies, The Journal of Immunology, vol. 127, No. 6, Dec. 1981, pp. 2401-2409.
Timonen et al., Characteristics of Human Large Granular Lymphocytes and Relationship to Natural Killer and K Cells, J. Exp. Med. The Rockefeller University Press, vol. 153, Mar. 1981, pp. 569-582.
Reeves et al., Intracellular Disruption of Rat Heart Lysosomes by Leucine Methyl Ester: Effects on Protein Degradation, Proc. Natl. Acad. Sci. USA, vol. 78, No. 7, pp. 4426-4429.
Herberman et al., Natural Killer Cells: Their Role in Defenses Against Disease, Science 214, 24, 1981.
Dokhelar et al., Natural Killer Cell Activity in Human Bone Marrow Recipients, Transplantation, vol. 31, No. 1, pp. 61-65.
Grimm et al., Lymphokine-Activated Killer Cell Phenomenon, Journal of Experimental Medicine, vol. 155, Jun. 1982, pp. 1823-1841.
Warner et al., Effects of a Cloned Cell Line with NK Activity on Bone Marrow Transplants, Tumour Development and Metastasis In Vitro, Nature, vol. 300, pp. 31-34.
Hiserodt et al., Differential Effects of Various Pharmacologic Agents on the Cytolytic Reaction Mechanism of the Human Natural Killer Lymphocyte: Further Resolution of Programming for Lysis and Immunology, vol. 129, No.5, Nov. 1982, pp. 2266-2270.
Quan et al., Studies on the Mechanism of NK Cell Lysis, The Journal of Immunology, vol. 128, No. 4, Apr. 1982, pp. 1786-1791.
Seaman et al., Suppression of Natural Killing In Vitro by Monocytes and Polymorphonuclear Leukocytes, The Journal of Clinical Investigation, vol. 69, Apr. 1982, pp. 876-888.
Dempsey et al., The Differential Effects of Human Leukocytic Pryogen/Lymphocyte-Activating Factor, T Cell Growth Factor, and Interferon on Human Natural Killer Activity, The Journal of Immunology vol. 129, No. 6, Dec. 1982, pp. 2504-2510.
Koren et al., Modulation of Human NK Cells by Interferon and Prostaglandin E.sub.2, Molecular Immunology, Vol. 19, No. 10, pp. 1341-1346.
Katz et al., Mechanisms of Human Cell-Mediated Cytotoxicity, The Journal of Immunology, vol. 129, No. 1, Jul. 1982, pp. 287-296.
Hiserodt et al., Characterization of the Cytolytic Reaction Mechanism of the Human Natural Killer (NK) Lymphocyte: Resolution into Binding, Programming, and Killer Cell-Independent Steps, The Journal of Immunology, vol. 129, No. 4, Oct. 1982, pp. 1781-1787.
Bonavida et al., Molecular Interactions in T-Cell-Mediated Cytotoxicity, Immunological Rev. vol. 72, pp. 119-141.
Podack et al., Assembly of Two Types of Tubules with Putative Cytolytic Function by Cloned Natural Killer Cells, Nature, vol. 302, Mar. 31, 1983, pp. 442-445.
Dennert et al., Cytolysis by H-2-Specific T Killer Cells, J. Exp. Med. The Rockefeller University Press, vol. 157, May 1983, pp. 1483-1495.
Burns et al., Human Natural Killer Cells, Activated Lymphocyte Killer Cells, and Monocytes Process Similar Cytotoxic Mechanisms, Proc. Natl. Acad. Sci. USA, vol. 80, Dec. 1983, pp. 7606-7610.
Hattori et al., Inhibition of Human Natural Killer (NK) Activity and Antibody Dependent Cellular Cytotoxicity (ADCC) by Lipomodulin, A Phospholipase Inhibitory Protein, The Journal of Immunology, vol. 131, No. 2, Aug. 1983, pp. 662-665.
Perussia et al., Human Natural Killer Cells Analyzed by B73.1, A Monoclonal Antibody Blocking Fc Receptor Functions, The Journal of Immunology, vol. 130, No. 5, May 1983, pp. 2133-2141.
Seaman, H
Lipsky Peter E.
Thiele Dwain L.
Board of Regents University of Texas System
Lee Lester L.
Maebius Stephen B.
LandOfFree
Hydrophobic peptide esters and amides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydrophobic peptide esters and amides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydrophobic peptide esters and amides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2386004